Stockscreener 앱 받기
15.60
2.90%
0.43
Tonix Pharmaceuticals Holding Corp 주식(TNXP)의 최신 뉴스
How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockBreakout Watch & Verified Momentum Watchlists - ulpravda.ru
Take Profit: How analysts rate Tonix Pharmaceuticals Holding Corp. stock todayWeekly Market Outlook & Long Hold Capital Preservation Plans - ulpravda.ru
Will Tonix Pharmaceuticals Holding Corp. stock see insider buyingWatch List & Stepwise Swing Trade Plans - ulpravda.ru
Can Tonix Pharmaceuticals Holding Corp. stock withstand economic slowdownJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
How analysts rate Tonix Pharmaceuticals Holding Corp. stock today2025 Key Highlights & Trade Opportunity Analysis - ulpravda.ru
Trading Systems Reacting to (TNXP) Volatility - Stock Traders Daily
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - The Manila Times
Tonix highlights pathway for potential single-dose, seasonal protection against Lyme Disease - Proactive financial news
Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results - MSN
Aug Gainers: How Tonix Pharmaceuticals Holding Corp stock reacts to inflationary pressuresMarket Activity Recap & Weekly Watchlist for Hot Stocks - moha.gov.vn
Tonix prices 615,025 shares at $16.26 in registered direct offering - Yahoo Finance
Tonix Pharma announces $20 million registered direct offering - MSN
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals secures $20 million investment from Point72 By Investing.com - Investing.com Nigeria
Tonix Pharma advances TNX-4800 Lyme disease program - MSN
Tonix Pharma Announces $20 Million Registered Direct Offering - TipRanks
Form 424B5 Tonix Pharmaceuticals - StreetInsider
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug - Asianet Newsable
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Tonix Pharmaceuticals (TNXP) Secures $20 Million Investment - GuruFocus
Tonix Pharmaceuticals (TNXP) Unveils Updates on Lyme Disease Tre - GuruFocus
Tonix Pharmaceuticals Prices $20 Million Registered Direct Offering - marketscreener.com
Tonix Pharmaceuticals shares fall 6.4% premarket after co prices stock and warrant offering - marketscreener.com
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention - Investing.com
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewswire
Drugmaker behind new fibromyalgia drug raises $20M for pipeline - Stock Titan
Tonix Pharmaceuticals Announces Updates on TNX-4800 for Lyme Disease Prevention - TradingView — Track All Markets
Tonix Pharmaceuticals Advances TNX-4800 Development for Lyme Disease Prevention Planning Clinical Trials for Innovative Monoclonal Antibody Therapy - Quiver Quantitative
A single shot to prevent Lyme each year? Inside Tonix’s antibody plan - Stock Titan
Avoiding Lag: Real-Time Signals in (TNXP) Movement - Stock Traders Daily
TNXP (Tonix Pharmaceuticals Holding) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2025) - GuruFocus
Tonix licenses global rights to novel non-opioid neuropathic pain drug TNX-4900 - Proactive financial news
Noble Financial Has Positive Outlook of TNXP FY2025 Earnings - MarketBeat
Published on: 2025-12-22 01:46:59 - Улправда
How Tonix Pharmaceuticals Holding Corp. stock benefits from tech adoptionJuly 2025 Summary & Low Risk Growth Stock Ideas - DonanımHaber
How Tonix Pharmaceuticals Holding Corp. stock reacts to inflationary pressuresMarket Growth Report & Verified Momentum Stock Watchlist - DonanımHaber
Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail tradersAnalyst Upgrade & Safe Entry Trade Reports - Улправда
Tonix licenses S1R antagonist from Rutgers University - BioWorld MedTech
Tonix Pharma secures rights to TNX-4900 for pain management - MSN
Tonix Pharmaceuticals licenses worldwide rights to non-opioid pain drug By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Secures Global Rights for Promising Pain Treatment - GuruFocus
Tonix Pharmaceuticals Licenses Non-Opioid Pain Medicine Candidate From Rutgers University - marketscreener.com
Tonix Pharma Secures Rights to TNX-4900 for Pain Management - TipRanks
Tonix Pharmaceuticals licenses worldwide rights to non-opioid pain drug - Investing.com
Tonix Pharmaceuticals Licenses TNX-4900 for Neuropathic Pain - TradingView — Track All Markets
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University - The Manila Times
Tonix Pharmaceuticals Licenses TNX-4900, a Non-Opioid Analgesic with Promising Efficacy and Safety Profile for Neuropathic Pain - Quiver Quantitative
Tonix Pharmaceuticals announces licensing TNX-4900 - marketscreener.com
Tonix Pharmaceuticals Holding Corp. Announces That It Licensed Exclusive Rights to Its Tnx-4900 Product Candidate for Chronic Neuropathic Pain from Rutgers University - marketscreener.com
[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event | TNXP SEC FilingForm 8-K - Stock Titan
Tonix Pharmaceuticals Announces Licensing TNX-4900, a - GlobeNewswire
(TNXP) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Equities Analysts Offer Predictions for TNXP FY2025 Earnings - MarketBeat
0.37%
자본화:
|
볼륨(24시간):